1-(N-Boc)-4(S)-azido-pyrrolidine-2(S)-methyl alcohol | 418793-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(N-Boc)-4(S)-azido-pyrrolidine-2(S)-methyl alcohol
• 英文别名: N-Boc-4S-azido-prolinol；(2S,4s)-4-azido-2-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester；tert-butyl (2S,4S)-4-azido-2-(hydroxymethyl)pyrrolidine-1-carboxylate
• CAS: 418793-92-7
• 化学式: C₁₀H₁₈N₄O₃
• 分子量: 242.278
• InChiKey: TYVPMGGBXKDZAF-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(N-Boc)-4(S)-azido-pyrrolidine-2(S)-methyl alcohol 在 咪唑 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 10.5h， 生成 (2S,4S)-tert-butyl 4-amino-2-((tert-butyl-dimethylsilyloxy)methyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  C3′-endo-puckered pyrrolidine containing PNA has favorable geometry for RNA binding: Novel ethano locked PNA (ethano-PNA)

  摘要：

  A novel peptide nucleic acid (PNA) analogue is designed with a constraint in the aminoethyl segment of the aegPNA backbone so that the dihedral angle beta is restricted within 60-80 degrees, compatible to form PNA:RNA duplexes. The designed monomer is further functionalized with positively charged amino-/guanidino-groups. The appropriately protected monomers were synthesized and incorporated into aegPNA oligomers at predetermined positions and their binding abilities with cDNA and RNA were investigated. A single incorporation of the modified PNA monomer into a 12-mer PNA sequence resulted in stronger binding with complementary RNA over cDNA. No significant changes in the CD signatures of the derived duplexes of modified PNA with complementary RNA were observed. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.05.015
• 作为产物：
  描述：

  (2S,4S)-1-叔丁基二甲基4-氨基吡咯烷-1,2二羧酸 在 锂硼氢 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成 1-(N-Boc)-4(S)-azido-pyrrolidine-2(S)-methyl alcohol
  参考文献：
  名称：

  MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE

  摘要：

  本发明提供了一种式(I)化合物： 或其药学上可接受的盐；包含式(I)化合物与适宜载体、稀释剂或赋形剂的药物组合物；以及治疗生理障碍，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾病的方法，包括给予式(I)化合物或其药学上可接受的盐。

  公开号：

  US20090163472A1

文献信息

• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• Synthesis of 4( S )-( N -Boc-amino)-2( S / R )-(thymin-1-ylmethyl)-pyrrolidine- N -1-acetic acid: a novel cyclic PNA with constrained flexibility
  作者：Moneesha D'Costa、Vaijayanti Kumar、Krishna N Ganesh

  DOI：10.1016/s0040-4039(01)02262-6

  日期：2002.1

  the pyrrolidyl ring could lead to pre-organization of the PNA structure and thus pose entropic advantages in binding to complementary nucleic acids. We report herein the synthesis of 4(S)-(N-Boc-amino)-2(S/R)-(thymin-1-ylmethyl)-pyrrolidine-N-1-acetic acids, their site-specific incorporation into PNA oligomers and their preliminary DNA binding properties.

  吡咯烷基PNA的出现是由于我们努力实现与互补核酸结合时氨基乙基缩水甘油基PNA结构的最佳微调。每个单元中的两个手性中心可产生四个非对映异构体，从而形成一个PNA单体和低聚物库。吡咯烷基环上的氮原子在生理pH下部分带电，导致产生阳离子PNA，这也导致水溶性增加。由吡咯烷基环引入的限制可能导致PNA结构的预组织，因此在与互补核酸结合方面具有熵的优势。我们在此报告4（S）-（N -Boc-氨基）-2（S / R）-（胸腺素-1-基甲基）-吡咯烷-N的合成-1-乙酸，它们在PNA低聚物中的位点特异性掺入及其初步的DNA结合特性。
• Stable NAD/NADH derivatives
  申请人：Roche Diabetes Care, Inc.

  公开号：US09399790B2

  公开（公告）日：2016-07-26

  The present invention provides for stable nicotinamide adenine dinucleotide (NAD/NADH) and nicotinamide adenine dinucleotide phosphate (NADP/NADPH) derivatives of formula (I), enzyme complexes of these derivatives and their use in biochemical detection methods and reagent kits.

  本发明提供了公式(I)稳定的烟酰胺腺嘌呤二核苷酸（NAD/NADH）和烟酰胺腺嘌呤二核苷酸磷酸（NADP/NADPH）衍生物，这些衍生物的酶复合物以及它们在生化检测方法和试剂盒中的使用。
• Mineralocorticoid receptor antagonists and methods of use
  申请人：Eli Lilly and Company

  公开号：US07994164B2

  公开（公告）日：2011-08-09

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本发明提供了公式(I)的化合物：或其药学上可接受的盐；包含公式(I)化合物与适当的载体、稀释剂或赋形剂的药物组合物；以及治疗生理障碍，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾脏疾病的方法，包括给予公式(I)化合物或其药学上可接受的盐。
• STABLE NAD/NADH DERIVATIVES
  申请人：Heindl Dieter

  公开号：US20080213809A1

  公开（公告）日：2008-09-04

  The present invention provides for stable nicotinamide adenine dinucleotide (NAD/NADH) and nicotinamide adenine dinucleotide phosphate (NADP/NADPH) derivatives of formula (I), enzyme complexes of these derivatives and their use in biochemical detection methods and reagent kits.